A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Massimo Cristofanilli, V. Valero, Asha Mangalik et al. · Journal of Clinical Oncology · 2008

1012 Background: Preclinical data provide evidence that suggests crosstalk between growth factor receptor pathways and the estrogen receptor (ER). Inhibition of both epidermal growth factor receptor and ER signalling may thus be a potential intervention to overcome hormonal resistance. We performed a phase II study to evaluate efficacy and tolerability of anastrozole (Arimidex) plus gefitinib (IRESSA) [A+G] vs. anastrozole plus placebo [A+P] for treatment of newly diagnosed HR+ MBC in postmenopausal women. Methods: A total of 94 women with newly diagnosed HR+ MBC were randomized (1:1) (one woman died prior to treatment) to receive anastrozole 1 mg/day and either gefitinib 250 mg/day or placebo (50 to A+P; 43 to A+G). Hormone receptor status was reviewed at a central laboratory. Primary endpoint was progression-free survival (PFS) and secondary endpoints included objective response rate (RECIST criteria) and clinical benefit rate (CBR; defined as objective response or stable disease ≥24 weeks), overall survival, safety and tolerability. Enrollment was stopped early due to slow recruitment and hence limited statistical analyses were performed. Results: A marked PFS advantage was seen for A+G over A+P (hazard ratio [A+G:A+P] 0.55, 95% CI 0.32–0.94, median 14.5 m vs 8.2 m). A numerical advantage in CBR was seen for A+G vs. A+P. Safety and tolerability profiles showed no unexpected findings. Treatment-related adverse events (AE) were seen in 79% of patients in the A+G arm vs. 38% in the A+P arm and were mostly mild. Two patients in the A+G arm and 1 patient in the A+P arm experienced an AE with outcome of death; none were considered treatment related. Conclusions: Anastrozole plus gefitinib was well tolerated and associated with a marked advantage in PFS vs. anastrozole plus placebo in postmenopausal women with newly diagnosed HR+ MBC. The data suggests the need for further investigation of this combination. Anastrozole plus gefitinib (n = 43) Anastrozole plus placebo (n = 50) Complete response (CR), n (%) 1 (2) 1 (2) Partial response (PR), n (%) 0 (0) 5 (10) Stable disease ≥ 24 weeks (SD), n (%) 20 (47) 11 (22) Clinical benefit rate (CR+PR+SD), n (%) 21 (49) 17 (34) 95% CI for clinical benefit rate 33–65 21–49 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca

Cited by 43 works. doi:10.1200/jco.2008.26.15_suppl.1012

Authors